About this trial

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

Eligibility criteria

Qualifiers

Patients with hematologic malignancies

At least 18 years old

Disqualifiers

Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

300 Participants
are grouped into 2 trial groups

Locations

2
Meir Medical Center4428164, Kfar Saba Israel
Rabin Medical Center49100, Petah Tikva Israel

Sponsors and collaborators

Meir Medical Center

Lead sponsor

Children's Hospital Medical Center, Cincinnati

Collaborator

Rabin Medical Center

Collaborator

Sheba Medical Center

Collaborator

Schneider Children's Medical Center, Israel

Collaborator